EMA Publishes First Quarterly Report Tracking EU Clinical Trial Targets Against 2030 Benchmarks

Sponsors running multinational trials in the EU now have a formal performance baseline to read against: EMA, the European Commission, and the Heads of Medicines Agencies have jointly released the first quarterly report under the EU's 2030 clinical trial target framework, covering activity from 1 January to 31 March 2026. The publication signals a shift toward structured, evidence-based accountability for the EU's clinical research authorisation system.

The headline figures are directionally positive but underscore how much ground remains. Nineteen multinational trials were authorised above the historical average during the quarter, against a cumulative target of 500 additional multinational trials by end-2030. On recruitment timelines, 40.5% of trials are currently recruiting within 200 days of application submission; the 2030 target is 66%. Preliminary data collected after March 2026 indicate continued upward movement across both indicators, though the report stops short of projecting a trajectory.

For regulatory affairs leads, the structural context matters as much as the numbers. The targets are explicitly aligned with the proposed EU Biotech Act, which prioritises acceleration of clinical trial authorisation across member states. Running in parallel, the FAST-EU pilot, led by HMA, gives sponsors a live opportunity to test compressed evaluation timelines for multinational submissions within the existing legal framework, without waiting for legislative change.

The quarterly cadence itself carries operational weight. ACT EU governance will conduct annual reviews drawing on these reports, with scope to recalibrate targets if the evidence warrants it. For sponsors designing multinational protocols or planning submission timelines into 2027 and beyond, the 200-day recruitment threshold and the multinational trial count will function as the primary system-performance signals to monitor each quarter.

The next quarterly report, expected to cover April through June 2026, will provide the first comparative data point against this baseline, making it the more consequential read for sponsors assessing whether authorisation timelines are compressing at a pace that affects study start-up planning.

Source: EMA via ema.europa.eu, 20 May 2026.